Cost-effectiveness of maintenance niraparib with an individualized starting dosage in patients with platinum-sensitive recurrent ovarian cancer in China

被引:0
|
作者
Shi, Yin [1 ,2 ,3 ]
Xiao, Di [1 ,2 ,3 ]
Li, Shuishi [2 ,4 ]
Liu, Shao [1 ,2 ,3 ]
Zhang, Yu [5 ,6 ]
机构
[1] Cent South Univ, Xiangya Hosp, Dept Pharm, Changsha, Peoples R China
[2] Cent South Univ, Xiangya Hosp, Natl Clin Res Ctr Geriatr Disorders, Changsha, Peoples R China
[3] Hunan Inst Pharm Practice & Clin Res, Changsha, Peoples R China
[4] Cent South Univ, Xiangya Hosp, Dept Gen Surg, Changsha, Peoples R China
[5] Cent South Univ, Xiangya Hosp, Dept Gynecol, Changsha, Peoples R China
[6] Gynecol Oncol Res & Engn Ctr Hunan Prov, Changsha, Peoples R China
基金
中国国家自然科学基金;
关键词
niraparib; routine surveillance; ovarian cancer; maintenance therapy; cost-effectiveness; THERAPY;
D O I
10.3389/fphar.2023.1198585
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: Niraparib improved survival in platinum-sensitive recurrent ovarian cancer (PSROC) patients versus routine surveillance, accompanied by increased costs. Based on the NORA trial, we evaluated for the first time the cost-effectiveness of maintenance niraparib with individualized starting dosage (ISD) in China.Methods: A Markov model was developed to simulate the costs and health outcomes of each strategy. The total costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs) were measured. One-way and probabilistic sensitivity analysis were performed to estimate model robustness. Scenario analyses were also conducted.Results: Compared to routine surveillance, niraparib additionally increased QALYs by 0.59 and 0.30 in populations with and without germline BRCA (gBRCA) mutations, with incremental costs of $10,860.79 and $12,098.54, respectively. The ICERs of niraparib over routine surveillance were $18,653.67/QALY and $39,212.99/QALY. At a willingness-to-pay (WTP) threshold of $37,488/QALY, the ISD enhanced the likelihood of cost-effectiveness from 9.35% to 30.73% in the gBRCA-mutated group and from 0.77% to 11.74% in the non-gBRCA mutated population. The probability of niraparib being cost-effective in the region with the highest per capita Gross Domestic Product (GDP) in China was 74.23% and 76.10% in the gBRCA-mutated and non-gBRCA mutated population, respectively. Niraparib was 100% cost-effective for National Basic Medical Insurance beneficiaries under the above WTP thresholds.Conclusion: Compared to routine surveillance, the ISD of niraparib for maintenance treatment of PSROC is cost-effective in the gBRCA-mutated population and more effective but costly in the non-gBRCA mutated patients. The optimized niraparib price, economic status, and health insurance coverage may benefit the economic outcome.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] Real-world data on niraparib maintenance treatment in patients with non-gBRCA mutated platinum-sensitive recurrent ovarian cancer
    Vilming, Bente
    Fallas Dahl, Jorgen
    Bentzen, Anne Gry
    Ingebrigtsen, Vibeke Anett
    Berge Nilsen, Elisabeth
    Vistad, Ingvild
    Dorum, Anne
    Solheim, Olesya
    Bjorge, Line
    Zucknick, Manuela
    Aune, Guro
    Lindemann, Kristina
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 (12) : 1898 - 1905
  • [32] Cost-effectiveness of homologous recombination defect testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer
    Alvarez-Secord, A.
    Barnett, J.
    Ledermann, J.
    Peterson, B.
    Myers, E.
    Havrilesky, L.
    GYNECOLOGIC ONCOLOGY, 2012, 125 : S92 - S93
  • [34] Individualized starting dose of niraparib in Chinese patients with platinum-sensitive recurrent ovarian cancer (PSROC): A randomized, double-blind, placebo-controlled, phase III trial (NORA)
    Wu, X.
    Zhu, J.
    Yin, R.
    Yang, J.
    Liu, J.
    Wang, J.
    Wu, L.
    Liu, Z.
    Gao, Y.
    Wang, D.
    Lou, G.
    Yang, H.
    Zhou, Q.
    Kong, B.
    Huang, Y.
    Chen, L.
    Li, G.
    An, R.
    Wang, K.
    Zhang, Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S1160 - S1161
  • [35] Progression-free survival of niraparib in patients with platinum-sensitive recurrent ovarian cancer: meta-analysis
    Purushotama, N. B. S. A.
    Budianto, C. J.
    Sabran, M. Z.
    Hutauruk, C. E. O. L.
    Kurniawan, A.
    Huang, I.
    ANNALS OF ONCOLOGY, 2024, 35 : S1403 - S1403
  • [36] Niraparib in Japanese patients with platinum-sensitive recurrent ovarian cancer: final results of a multicenter phase 2 study
    Itamochi, Hiroaki
    Takeshima, Nobuhiro
    Hamanishi, Junzo
    Hasegawa, Kosei
    Matsuura, Motoki
    Miura, Kiyonori
    Nagao, Shoji
    Nakai, Hidekatsu
    Tanaka, Naotake
    Tokunaga, Hideki
    Nishio, Shin
    Watari, Hidemichi
    Yokoyama, Yoshihito
    Kase, Yoichi
    Sumino, Shuuji
    Kato, Ai
    Suri, Ajit
    Yasuoka, Toshiaki
    Takehara, Kazuhiro
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2024, 35 (05)
  • [37] Management of platinum-sensitive recurrent ovarian cancer
    Pfisterer, Jacobus
    Ledermann, Jonathan A.
    SEMINARS IN ONCOLOGY, 2006, 33 (02) : S12 - S16
  • [38] Safety assessment of niraparib individualized starting dose in patients with platinum-sensitive recurrent ovarian cancer: A randomized, double-blind, placebo-controlled, phase III NORA trial.
    Wang, Jing
    Wu, Xiaohua
    Zhu, Jianqing
    Yin, Rutie
    Yang, Jiaxin
    Huang, Qidan
    Wu, Lingying
    Liu, Ziling
    Gao, Yunong
    Wang, Danbo
    Lou, Ge
    Yang, Hongying
    Zhou, Qi
    Kong, Beihua
    Huang, Yi
    Chen, Lipai
    Li, Guiling
    An, Ruifang
    Tan, Tao
    Dong, Juan
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [39] ENGOT-OV16/NOVA: A MAINTENANCE STUDY WITH NIRAPARIB VERSUS PLACEBO IN PATIENTS WITH PLATINUM-SENSITIVE OVARIAN CANCER
    Matulonis, U.
    Herrstedt, J.
    Oza, A.
    Mahner, S.
    Redondo, A.
    Fabbro, M.
    Ledermann, J.
    Lorusso, D.
    Vergote, I.
    Rosengarten, O.
    Reinthaller, A.
    Madry, R.
    Monk, B. J.
    Dorum, A.
    Tinker, A. V.
    DuBois, A.
    Gonzalez Martin, A.
    Follana, P.
    Berek, J. S.
    Gilbert, L.
    Benigno, B.
    Rosenberg, P.
    Rimel, B. J.
    Buscema, J.
    Balser, J.
    Agarwal, S.
    Mirza, M. R.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2016, 26 : 19 - 20
  • [40] Effect of niraparib on cardiac repolarization in patients with platinum-sensitive, recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer
    Moore, Kathleen
    Chan, John K.
    Secord, Angeles Alvarez
    Patel, Manish R.
    Callahan, Timothy
    Guo, Wei
    Zhang, Zhi-Yi
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 83 (04) : 717 - 726